Jupiter Neurosciences Expands Brain Health Market with Clinically-Backed Nugevia Supplement Line

Jupiter Neurosciences Inc. (NASDAQ: JUNS) is expanding its brain health expertise beyond pharmaceutical development with the launch of Nugevia, a direct-to-consumer longevity product line focused on mitochondrial support, mental clarity, and beauty from within. The clinical-stage pharmaceutical company, known for developing JOTROL™, an enhanced orally administered resveratrol formulation, is now targeting consumer wellness markets with scientifically formulated supplements derived from its core research.

At the center of this consumer initiative is Nugevia MND, a cognitive health supplement expected to account for approximately 60% of the company's sales volume. The formulation builds directly on Jupiter Neurosciences' pharmaceutical expertise in neuroinflammation and central nervous system function, addressing the same biological pathways that define both aging and cognition. A company spokesperson emphasized that brain health is central to Jupiter's DNA as a neuroscience company, noting that consumer awareness in this area is accelerating rapidly amid growing demand from aging populations and proactive consumers seeking mental clarity, focus, and resilience.

The global brain health supplement market reflects this expanding demand, projected to reach about $23 billion by 2030 with a compound annual growth rate of approximately 13%. This growth is driven by increasing recognition that maintaining cognitive vitality is fundamental to quality of life as populations age and life expectancy increases. People are becoming more aware that living longer requires efforts to stay mentally sharp and emotionally engaged, with brain function driving every aspect of performance from focus and memory to motivation and resilience.

All Nugevia products are derived from JOTROL, Jupiter Neurosciences' proprietary resveratrol formulation designed to deliver therapeutically relevant, safe levels of the compound. While resveratrol has been available for years, the company overcame previous limitations by developing a delivery system that provides approximately nine times higher absorption and proven central nervous system penetration. This scientific breakthrough enables Jupiter Neurosciences to reintroduce resveratrol with clinically validated science, addressing previous concerns about bioavailability.

Beyond its antioxidant and anti-inflammatory effects, resveratrol activates PARP-1, an important protein in DNA repair and stress response, while also improving cardiovascular health, enhancing cognitive function, and providing antibacterial and antiviral properties against food-borne pathogens. JOTROL represents a first-in-class oral therapeutic that reaches effective levels in the brain, increases energy metabolism, induces mitochondrial biogenesis, and reduces inflammation. Phase one trials determined the drug was safe and well-tolerated at all dose levels, demonstrating blood plasma levels 8-10-fold higher than naïve resveratrol administered in historical clinical trials.

Jupiter Neurosciences distinguishes its supplement line through precision-engineered intelligent stacking of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization. The company's supplement portfolio includes Nugevia MND, Nugevia GLO, and Nugevia PWR, all backed by clinical data and supported by well-known users including former tennis champion Annika Sörenstam, NBA legend Chris Webber, scientist Charbel Moussa, and biohacker Jean Fallacara. These ambassadors represent diverse audiences from elite athletes to entrepreneurs, demonstrating the products' applicability across different lifestyles.

The company emphasizes that its entry into the supplement space is unique because it originates from clinical research rather than consumer marketing. A spokesperson noted that Jupiter Neurosciences is first and foremost a clinical-stage biotech company that has spent the past decade developing therapies for complex central nervous system disorders, making its consumer products a natural evolution of its dual-path strategy: advancing prescription therapies for patients while empowering everyday consumers with credible, evidence-based solutions for healthy aging.